The role of high mobility group box 1 in neuroinflammatory related diseases

被引：28

作者：

Mo, Jialu ^{[1
]}

Hu, Jiao ^{[1
]}

Cheng, Xianglin ^{[1
]}

机构：

[1] Yangtze Univ, Affiliated Hosp 1, Jingzhou 434000, Hubei, Peoples R China

来源：

BIOMEDICINE & PHARMACOTHERAPY | 2023年 / 161卷

关键词：

Neuroinflammation; High mobility group box 1; Toll-like receptor 4; Receptor for advanced glycation endproducts; MONOCLONAL-ANTIBODY; EXPRESSION LEVEL; PROTEIN HMGB1; TNF-ALPHA; EPILEPSY; MODEL; AUTOPHAGY; DAMAGE;

D O I：

10.1016/j.biopha.2023.114541

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

High mobility group box 1 (HMGB1) is a ubiquitous and highly conserved non-histone DNA-binding protein with different biological functions according to its subcellular localization. It is widely believed that HMGB1, which is released into the extracellular space, plays a key role in the inflammatory response. In recent years, numerous studies have shown that the development of various neurological diseases such as epilepsy, Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), cerebrovascular disease and traumatic brain injury (TBI) are inextricably linked to inflammation. We will review the mechanisms of HMGB1 and its receptors in nervous system inflammation to provide a basis for further development of new HMGB1-based therapies.

引用

页数：11

共 112 条

[1] Astrocyte-endothelial interactions at the blood-brain barrier [J].

Abbott, NJ ;

Rönnbäck, L ;

Hansson, E .

NATURE REVIEWS NEUROSCIENCE, 2006, 7 (01) :41-53

[2] HMGB1/RAGE/TLR4 axis and glutamate as novel targets for PCSK9 inhibitor in high fat cholesterol diet induced cognitive impairment and amyloidosis [J].

Abuelezz, Sally A. ;

Hendawy, Nevien .

LIFE SCIENCES, 2021, 273

[3] Meta-Analysis of Methamphetamine Modulation on Amyloid Precursor Protein through HMGB1 in Alzheimer's Disease [J].

Alabed, Sedra ;

Zhou, Heping ;

Sariyer, Ilker K. ;

Chang, Sulie L. .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (09)

[4] Rethinking carbamazepine oral delivery using polymer-lipid hybrid nanoparticles [J].

Ana, Raquel ;

Mendes, Maria ;

Sousa, Joao ;

Pais, Alberto ;

Falcao, Amilcar ;

Fortuna, Ana ;

Vitorino, Carla .

INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2019, 554 :352-365

[5] The aetiologies of epilepsy [J].

Balestrini, Simona ;

Arzimanoglou, Alexis ;

Bluemcke, Ingmar ;

Scheffer, Ingrid E. ;

Wiebe, Samuel ;

Zelano, Johan ;

Walker, Matthew C. .

EPILEPTIC DISORDERS, 2021, 23 (01) :1-16

[6] Dysregulation of Astrocytic HMGB1 Signaling in Amyotrophic Lateral Sclerosis [J].

Brambilla, Liliana ;

Martorana, Francesca ;

Guidotti, Giulia ;

Rossi, Daniela .

FRONTIERS IN NEUROSCIENCE, 2018, 12

[7] HMGB1 as a potential new marker of disease activity in patients with multiple sclerosis [J].

Bucova, Maria ;

Majernikova, Beata ;

Durmanova, Vladimira ;

Cudrakova, Daniela ;

Gmitterova, Karin ;

Lisa, Iveta ;

Klimova, Eleonora ;

Kluckova, Kristina ;

Buc, Milan .

NEUROLOGICAL SCIENCES, 2020, 41 (03) :599-604

[8] TOLL-LIKE RECEPTOR SIGNALING IN AMYOTROPHIC LATERAL SCLEROSIS SPINAL CORD TISSUE [J].

Casula, M. ;

Iyer, A. M. ;

Spliet, W. G. M. ;

Anink, J. J. ;

Steentjes, K. ;

Sta, M. ;

Troost, D. ;

Aronica, E. .

NEUROSCIENCE, 2011, 179 :233-243

[9] The mechanism of HMGB1 secretion and release [J].

Chen, Ruochan ;

Kang, Rui ;

Tang, Daolin .

EXPERIMENTAL AND MOLECULAR MEDICINE, 2022, 54 (02) :91-102

[10] HMGB1 as a potential biomarker and therapeutic target for severe COVID-19 [J].

Chen, Ruochan ;

Huang, Yan ;

Quan, Jun ;

Liu, Jiao ;

Wang, Haichao ;

Billiar, Timothy R. ;

Lotze, Michael T. ;

Zeh, Herbert J. ;

Kang, Rui ;

Tang, Daolin .

HELIYON, 2020, 6 (12)

← 1 2 3 4 5 6 7 8 9 10 →